Join GSK, Novartis, Gilead, Ministry of Health(Germany), Ipsen, National Pharmacy Association

Evaluate HTA Reforms and Market Access Processes to Optimise Business Profit | 13-14 October 2014
SMi P&R 200 x 200
SMi P&R 200 x 200
Spread the Word
Listed Under

* Bussiness
* Pharmaceuticals
* Money
* Science

* Finance
* Science

* London - England - England

LONDON, England - June 12, 2014 - PRLog -- The growth in healthcare expenditure is outstripping GDP and is not sustainable in most countries. With the pharma industry facing different demands from regulatory bodies (such as the European EMA) and payers (including health technology assessment (HTA) bodies such as UK’s National Institute for Health and Care Excellence (NICE)), getting a drug approved is one thing but gaining access to the market and convincing payers of the value of the medicine is something else. Payers want to see evidence that a new drug is better than current treatment options.

Against this backdrop, now in its 20th year, this event has been one of the oldest market leaders in the pharmaceutical industries calendar for some time. Our expert speaking faculty; made up from key industry personnel from big pharma, biotech and academia will thoroughly explain and offer advice on P&R and market access. The 2014 agenda will focus on case studies as applied to different countries and environments in terms of market access.

Key Presenters Include:
Chairs for 2014:
• Peter Hertzman, Nordic Market Access Director, BMS
• Leslie Galloway, Chairman, Ethical Medicines Industry Group (EMIG)

Key Speakers:

• Leyla Hannbeck, Head of Pharmacy Services, National Pharmacy Association
• Silke Baumann, Head of Unit, Pricing, Assessment and Reimbursement of New Medicines, Ministry of Health, Germany
• Rodolphe Perard, Associate Director, Market Access, Gilead
• Francois Bernard, Head of Market Access, Mundipharma
• Mike Chambers, Head of Reimbursement and Value, Market Access and Healthcare Solutions, GlaxoSmithKline
• Linda Van Saase, Manager, Pharmaceutical Care, National Healthcare Institute
• Irma Van Den Arend, VP, Global Pricing, Reimbursement and Funding, Ipsen
• Mete Saylan, Senior Market Access Manager, Novartis

Benefits of Attending:

• Evaluate challenges within price discrimination
• Implications of AMNOG featuring IGES institut, EUCOPE and Ministry of Health, Germany
• Case study from Ipsen on latest developments in pharmaceutical pricing
• dpyuc Analyse the impact of Value Based Assessment on SMEs
• Gain further insight on how to engage effectively with payers
• Key presentation on the IMI GetReal Consortium
• Ample networking opportunities , including a drinks reception on the close of Day One sponsored by Quintiles


For more information please visit:

European Pharmaceutical Pricing and Reimbursement 2014
13-14 October, 2014
Marriott Regents Park Hotel, London, UK

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance, and Pharmaceutical industries.

We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.

More information can be found at

Daniel Lee
+44 20 7827 6078
Email:*** Email Verified
Tags:Bussiness, Pharmaceuticals, Money, Science
Industry:Finance, Science
Location:London - England - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: Jun 18, 2014
SMi Group Ltd. News
Daily News
Weekly News

Like PRLog?
Click to Share